electroCore Strengthens Patent Portfolio with Issuance of Four New U.S. PatentsGlobeNewsWire • 09/21/22
electroCore, Inc. (ECOR) CEO Dan Goldberger on Q2 2022 Results - Earnings Call TranscriptSeeking Alpha • 08/07/22
electroCore to Participate at Canaccord Genuity 42nd Annual Growth ConferenceGlobeNewsWire • 08/05/22
electroCore, Inc. Announces Study of gammaCore Sapphire™ for the Treatment of Post-COVID SyndromeGlobeNewsWire • 07/07/22
electroCore, Inc. Announces gammaCore™ Non-Invasive Vagus Nerve Stimulator Available Through National Spine and Pain CentersGlobeNewsWire • 05/24/22
electroCore, Inc. (ECOR) CEO Dan Goldberger on Q1 2022 Results - Earnings Call TranscriptSeeking Alpha • 05/09/22
electroCore Announces Publication of Investigator-Initiated Trial Data for SAVIOR-1 in COVID-19 Patients in Frontiers in NeurologyGlobeNewsWire • 04/21/22
gammaCore™ Non-Invasive Vagus Nerve Stimulation (nVNS) Selected for Department of Defense Biotech Optimized for Operational Solutions and Tactics (BOOST) ProgramGlobeNewsWire • 04/19/22
electroCore Announces Dr. Peter Staats to Keynote the Fifth Annual Bioelectronic Medicine Forum in New YorkGlobeNewsWire • 03/23/22
electroCore, Inc. (ECOR) CEO Daniel Goldberger on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/11/22
electroCore, Inc. Announces Three Abstracts to be Presented at International Stroke Conference 2022GlobeNewsWire • 01/25/22
ElectroCore's Vagus Nerve Stimulator Wins Breakthrough Device Tag For Stress DisorderBenzinga • 01/12/22
gammaCore™ Non-Invasive Vagus Nerve Stimulation(nVNS) Receives Breakthrough Device Designation for Treatment of Posttraumatic Stress Disorder (PTSD)GlobeNewsWire • 01/12/22